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The discovery of artemisinin (ART) for malaria treatment won the 2015 Nobel Prize in
Medicine, which inspired the rediscovery and development of ART for the treatment of
other diseases including cancer. In this study, we investigated the potential therapeutic
effect of ART and dihydroartemisinin (DHA) on multiple myeloma (MM) cells including
primary MM cells and in 5TMM3VT mouse model. Both in vitro and in vivo experiments
showed that DHA might be a more promising anti-MM agent with significantly improved
efficacy compared to ART. Mechanistic analyses suggested that DHA activated the
mitochondrial apoptotic pathway by interacting with ferrous (Fe2+) ions and oxygen to
produce reactive oxygen species (ROS). Intriguingly, DHA could reverse the upregulated
expression of B-cell lymphoma 2 (Bcl-2) protein, a typical mitochondrial apoptotic marker,
induced by dexamethasone (Dexa) in MM. We further demonstrated that DHA treatment
could overcome Dexa resistance and enhance Dexa efficacy in MM. Additionally,
DHA combined with Dexa resulted in increased ROS production and cytochrome C
translocation from the mitochondria to the cytoplasm, resulting in alterations to the
mitochondrial membrane potential and caspase-mediated apoptosis. In summary, our
study demonstrated that DHA was superior to ART in MM treatment and overcame
Dexa resistance both in vitro and in vivo, providing a promising therapeutic strategy for
MM therapy.
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INTRODUCTION
Multiple myeloma (MM) remains an incurable hematological malignancy of plasma cells, despite
the therapeutic advances over the past two decades with numerous agents including proteasome
inhibitors such as bortezomib (1), ixazomib (2), and carfilzomib (3), monoclonal antibodies such as
elotuzumab (4), and daratumumab (5), immunomodulatory drugs such as pomalidomide (6) and
lenalidomide (7), and other treatments including chimeric antigen receptors (CAR)-T-cell therapy
(8, 9) gaining clinical approval. Dexamethasone (Dexa) remains the most widely used drug for the
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treatment of MM despite the development of resistance in
patients after prolonged exposure to its high doses (10), which
in turn, is associated with poor prognosis of MM. Recurrent
MM patients treated with numerous anti-MM drugs or high-risk
patients with MM have poor median survival rates (11); thus,
novel molecular targeting therapies are required to overcome
drug resistance in MM treatment.
An increasing number of studies have demonstrated that
artemisinin (ART)-type based endoperoxide drugs exhibit
anticancer properties (12, 13). Dihydroartemisinin (DHA)-
inhibited proliferation of cancer cells may be associated with
the production of reactive oxygen species (ROS) (14, 15),
induction of apoptosis (16), inhibition of angiogenesis (17), and
ferroptosis (18). For example, in lung cancer, DHA-inhibited
proliferation induces cell cycle arrest and decreases tumor
growth by suppressing invasion and migration, increases the
concentration of calcium (Ca2+) ions, and activates p38 (19).
In glioma, DHA induces autophagy, apoptosis, and cell cycle
arrest by increasing the cleavage of caspase-3, decreasing the
expression of protein kinase B (p-AKT), and downregulating
AKT phosphorylation followed by caspase-3 activation (20).
Furthermore, artemisinin-type drugs increase the sensitivity of
resistant cancer cells to conventional drugs (21). Examples
of this include DHA combined with gemcitabine, which
is efficacious against pancreatic tumor cells by suppressing
gemcitabine-induced nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) activation (22); DHA combined
with cyclophosphamide, which inhibits spontaneous pulmonary
metastasis (23), and a combination of DHA and gemcitabine,
which decreases hepatoma tumor growth (24). However, the
synergistic effects of DHA with the conventional drug Dexa for
the treatment of MM have not yet been determined.
In the present study, two artemisinin-type drugs, ART and
DHA, were examined for their anti-MMeffect in vitro and in vivo.
We also established their mechanism of action.
MATERIALS AND METHODS
Cell Culture
Human MM cell lines MM.1S, MM.1R cells were purchased
from ATCC (CRL-2974 and CRL-2975, respectively), ARP1
and H929 cells were kind gifts from Dr. Siegfried Janz
(University of Iowa, Iowa City, IA, USA) and mouse 5TMM3VT
cells were donated by Dr. Wen Zhou (Xiangya School
of Medicine, Central South University, Key Laboratory of
Carcinogenesis and Cancer Invasion, Ministry of Education;
Key Laboratory of Carcinogenesis, National Health and Family
Planning Commission, Changsha, China). All the cells were
cultured in RPMI-1640 medium (Biological Industries, Beit
Haemek, Israel) supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Biological Industries, Israel) and 1%
penicillin/streptomycin at 37◦C with 5% CO2. Primary human
CD138+ cells were collected from the blood samples of each
participant and cultured in the same conditions as described
above, which was approved by the ethics committees of
Affiliated Hospital of Nanjing University of Chinese Medicine
(No. 2018NL-KS13).
Cell Proliferation Assay
Cell growth was evaluated using MTT assay according to the
method described in the literature (25). Cells were seeded at a
density of 8 × 103 cells/well in 96-well plates. MM cells were
cultured with different treatments for 48 h, and primary human
CD138+ cells were treated for 24 h at 37◦C with 5% CO2. 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 5
mg/mL) was added into each well. After incubation for 4 h, the
supernatant was removed and DMSO was added to dissolve
formazan. The absorbance was measured at A570 nm with a
microplate plate reader (Thermo Fisher Scientific, Inc., USA).
Apoptosis Assay
MM cells were seeded in 6-well plates with 2×106 cells
each well and treated with ART (Aladdin, Shanghai, China,
#A110206), DHA (MACKLIN, Shanghai, China, #D831931),
Dexa (Sigma-Aldrich, Merck KGaA, #D4902) or combination
of DHA with Dexa for 48 h. Cells were washed twice with
cold prechilled phosphate buffered saline (PBS), resuspended in
binding buffer [10 mmol/L HEPES/NaOH (pH 7.4), 140 mmol/L
NaCl, and 2.5 mmol/L CaCl2], and then stained with annexin-V-
FITC (20µg/mL) and Propidium Iodide (PI; 50µg/mL; Sigma-
Aldrich, Merck KGaA) for 15min in the dark. The number
of apoptotic cells was analyzed using flow cytometer (EMD
Millipore; USA; guavaSoft 3.1.1).
Cell Cycle Analysis
Cells were collected into centrifuge tubes and washed twice
with PBS, then fixed with 75% ethanol for 12 h. Subsequently,
cells were washed with PBS, treated with 200µg/mL RNase for
15min at 37◦C to remove RNA contamination, and stained with
50µg/mL PI (Sigma-Aldrich, Merck KGaA) for 30min at room
temperature in the dark. Cells were filtered through 35µmmesh
to remove clumps before analyzed by a flow cytometer.
Determination of 1ψm
Variations in mitochondrial membrane potential (1ψm) of MM
cells were measured using a JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzymidazolyl carbocyanine iodide) kit (Beyotime
Institute of Biotechnology, Jiangsu, China, #C2006). After treated
with 30µM DHA or 60µM Dexa for 48 h, a total of 2 × 106
cells were harvested and incubated with JC-1 at 37◦C for 20min
and then washed and re-suspended in PBS. The samples were
analyzed and 10,000 events were acquired with flow cytometer.
JC-1 is presented as monomers in low 1ψm (Ex = 549 nm, Em
= 590 nm), while it was presented as protomeric aggregates in
high 1ψm (Ex = 488 nm, Em = 530 nm). The loss of 1ψm
was rejected by increased green fluorescence from the JC-1
monomers (26).
Western Blot
Protein levels in MM cells were detected by western blot method,
which was performed as previously described (27). MM cells
were harvested, washed and lysed with assistance of RIPA Lysis
Buffer. 40 µg total protein samples were heated in SDS/β-
mercaptoethanol buffer and loaded on 12–15% SDS-PAGE gels.
Proteins were separated by electrophoresis in the gels, and
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then transferred onto PVDF membrane. The membrane was
blocked with 5% non-fat milk and incubated with primary
antibodies against Bcl-2 (Transduction laboratones, #610538,
1:1,000 dilution), Bad (Cell Signaling Technology, #9292,
1:1,000 dilution), PARP (Cell Signaling Technology, #9542S,
dilution rate1:1000), Caspase 3 (Cell Signaling Technology,
#9662s, 1:1,000 dilution), cytochrome C (Cyt C; Cell Signaling
Technology, #4272, 1:1,000 dilution), and β-actin(Cell Signaling
Technology, #4970S, 1:1,000 dilution) overnight at 4◦C. Blots
were incubated with secondary antibodies used horseradish
peroxidase conjugated rabbit anti-mouse (Affinity, #S0002,
1:10,000 dilution) or goat anti-rabbit IgG (Fcmacs, #FMS-Rb01,
1:10,000 dilution) for 1 h at room temperature. Finally, blots
were developed by chemiluminescence using ECL kit (Tanon,
Shanghai, China).
Mitochondrial Isolation Assay
Mitochondria isolation was operated according to the
manufacturer’s instruction of Cell Mitochondria Isolation
Kit (Beyotime Institute of Biotechnology, Jiangsu, China,
#C3601). MM.1S and MM.1R cells were plated in a 100 mm2
dish containing 5 × 108 cells and treated with DHA, Dexa
or combination of DHA with Dexa for 48 h. After treatment,
cells were washed with cold PBS for three times, then collected
into centrifuge tubes (1,200 g for 5min) and resuspended with
isolation buffer containing protease inhibitor (1:1,000, Biolegend,
America, CAT: 640941). After standing the suspension for
15min, the suspension of cells were homogenized by a Dounce
glass homogenizer for several complete up-and-down cycles
and kept on ice. Next, the liquid was transferred into centrifuge
tubes to remove debris including nuclei by centrifugation at
600 g for 10min at 4◦C. Then supernatant was transferred into
another centrifuge tube and centrifuged at 11,000 g for 10min at
4◦C. The pellet was the crude mitochondrial fraction. The crude
mitochondrial fraction was lysed by mitochondrial lysis fluid for
western blot analysis. After placed on ice for 15min, the lysate
was centrifuged at 12,000 g for 5min at 4◦C.
Oxygen Consumption Rate (OCR)
Measurement
O2k (Oroboros, Austria) was used for the measurement of OCR.
According to the manufacturer’s protocol (https://wiki.oroboros.
at/index.php/OROBOROS_INSTRUMENTS), 1 × 106/2mL
ARP1 and H929 cells were cultured for 48 h with 10µM
ART, 10µM DHA or untreated, respectively. The cell culture
medium was replaced with 1,640 medium without FBS, and
OCR measurement was performed in real time using software
(DatLab 7.0.0.1077, included in the O2k-FluoRespirometer). The
mitochondrial inhibitors, 2.5µM oligomycin (Aladdin, China,
#o111756), 1.0µM carbonyl cyanide 3-chlorophenylhydrazone
(FCCP, ACROS, America, #228131000), 0.5µM rotenone
(Aladdin, China, #R105076) and 2.5µM antimycin A (ENZO,
America, #alx-380-075-m005) were added in the listed order
(28). The OCR was calculated by the formula:(the max of
oxygen consumption after FCCP stimulation—the basal oxygen
consumption rate) / protein concentration.
Measurement of Fe2+ Levels
1× 106 cells were harvested and incubated with 5µMof Calcein-
AM (a non-fluorescent lipophilic ester, Yeasen, Shanghai, China,
#40719ES50) for 15min at 37◦C and 50µg/mL PI for 10min
at 4◦C after treated with 10µM ART or DHA for 48 h.
Cells were then washed twice using PBS and the fluorescence
intensity signals of the cells were analyzed using a flow
cytometry (wavelength of Ex = 490 nm / Em = 515 nm for
Calcein-AM; wavelength of Ex = 535 nm / Em = 617 nm
for PI). Cytosolic esterases hydrolyze Calcein-AM to release
the fluorescent calcein, which binds to the intracellular labile
iron pool, resulting in quenching of the fluorescent signal. The
cytosolic iron mobilization was calculated by the mean cellular
calcein fluorescent intensity using flow cytometry. The reduction
of calcein-AM fluorescence intensity represented an increase of
chelatable cytosolic Fe2+ (29).
ROS Determination
Intracellular ROS levels were quantified by measuring the
fluorescence intensity of the 2′,7′-dichlorofluorescein diacetate
(DCFH-DA; Beyotime Institute of Biotechnology, Jiangsu,
China, #S0033) with PI as a probe using flow cytometry.
The non-fluorescent DCFH-DA is deacetylated by intracellular
esterases to the non-fluorescent DCFH, which is subsequently
rapidly oxidized by intracellular ROS to the fluorescent 2′,7′-
dichlorofluorescein. Cells were washed twice with PBS and
incubated with 10µMDCFH-DA at 37◦C for 30min in the dark.
Subsequently, the cells were washed twice and resuspended in
PBS. ROS levels were determined using a flow cytometer.
Human Myeloma Xenograft Mice Model
All animal procedures were conducted in accordance with
government-published recommendations for the Care and Use
of Laboratory Animal, which were approved by the Institutional
Ethics Review Boards of Nanjing University of Chinese Medicine
(No. ACU170501 and 201905A003). MM.1S (sensitive to
Dexa) and MM.1R (resistant to Dexa) cells (3 × 106) were
subcutaneously injected into the abdominal area of 6∼8-weeks
old NOD-SCID mice (n = 10 per group) from Beijing Vital
River Laboratory Animal Technology, Co., Ltd (Beijing, China).
Starting on day 3 post cell transfer, mice were treated with
DHA (25 mg/kg) three times a week and Dexa (9 mg/kg) every
other day. The tumor volumes were measured using calipers at
the indicated time points. When the tumor diameters reached
20mm, the mice were sacrificed. Tumor volume (mm3) was
calculated as: (length× width2)/2 (30).
5TMM3VT Myeloma Mice Model
5TMM3VT murine myeloma cells (1 × 106) were injected
through the tail vein into 6-week-old C57BL/KaLwRij mice (n =
10 per group). The mice were divided into 3 groups as follows:
DHA (50 mg/kg) treatment group, ART (50 mg/kg) group, and
control group (Castor oil: ethanol: saline=2:1:7). After 2 days, 10
mice from each group were treated via intraperitoneal injection
three times a week for 75 days until all the mice were dead.
DHA and ART were dissolved in 70% saline, 20% Castor oil, and
10% ethanol.
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Statistical Analysis
Data were expressed as the mean ± SD. The Student’s t-test was
used to determine a significant difference. The difference between
groups was set at ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.
Mouse survival was analyzed by GraphPad Prism 5 software
(GraphPad Software Inc., La Jolla, CA, USA) using the Log-rank
(Mantel-Cox) Test. The interaction between DHA and Dexa was
analyzed by CalcuSyn software program (CalcuSyn Version 2.1,
Biosoft). Isobologram analysis was based on the Chou-Talalay
method with the combination index (CI). CI < 1.0 indicates
synergism, CI = 1.0 presents additive activity and CI > 1.0
states antagonism.
FIGURE 1 | DHA is a potential drug in the treatment of myeloma. (A) The survival data was obtained using 5TMM3VT myeloma mice model. (B) The MTT assay. DHA
could suppress the proliferation of ARP1 and H929 cells, while ART could not. (C,D) The cell cycle and apoptosis of MM cells with or without treatment of either DHA
or ART were determined by flow cytometry. The difference of the cell cycle of G2/M phase or apoptosis between groups was calculated by Student’s t-test. *P <
0.05, **P < 0.01, and ***P < 0.001 were considered statistically significant.
Frontiers in Oncology | www.frontiersin.org 4 May 2020 | Volume 10 | Article 767
Chen et al. Dihydroartemisinin for Multiple Myeloma
RESULTS
DHA Is a Potential Drug in the Treatment of
Myeloma
To evaluate the potential of ART or DHA as a treatment for
MM, the therapeutic effects of ART and DHA were determined
on overall survival rate of C57BL/KaLwRij MM-prone mouse
model established using 5TMM3VT cells. Kaplan–Meier survival
curve showed that the MM mice with ART treatment had
significantly improved overall survival (median survival, 53 days)
compared with the untreated control animals (median survival,
38 days; P = 0.0085). Additionally, MM mice treated with DHA
had a significantly longer survival (median survival >75 days)
compared with the untreated control animals (P= 0.0020). None
of the untreated control mice survived >6 weeks; however, mice
treated with ART survived for <8 weeks (39% increase) while
mice treated with DHA survived >10 weeks (90% increase).
The improved survival rate of DHA-treated mice compared with
those of ART-treatedmice (P= 0.0116; Figure 1A) demonstrated
the therapeutic potential of DHA compared with ART for the
treatment of MM.
The effects of ART and DHA on the proliferation of the
MM cell lines were determined (Figure 1B). Treatment of ARP1
and H929 cells with ART or DHA resulted in dose-dependent
cytotoxicity. The IC50 of ART was significantly higher than that
of DHA in both ARP1 (2.84mM vs. 2.937µM, respectively) and
H929 (815µM vs. 7.931µM)MM cells (Figure 1B), highlighting
the better efficacy of DHA in the treatment for MM. This
observation was further confirmed by performing a cell cycle
assay and apoptosis analysis. In the cell cycle assay, the
proportion of ART- and DHA-treated cells in the G2/M stages
decreased compared with that in the untreated control group,
and the proportion of ARP1 (15.23 ± 3.66%) and H929 cells
(11.46 ± 4.26%) in these phases was significantly lower in the
DHA-treated group than that in the ART-treated group (ARP1
cells: 28.40 ± 5.63%, P < 0.05 and (H929 cells: 29.97 ± 1.38%, P
< 0.01; Figure 1C). Flow cytometry analysis of apoptosis showed
that there was a significant increase in the apoptotic levels in the
DHA-treated ARP1 (25.83 ± 7.80%) and H929 cells (66.23 ±
1.80%) compared with the ART-treated ARP1 (9.08± 0.72%, P<
0.01) and H929 cells (12.54± 1.59%, P < 0.01) and the untreated
ARP1 (5.35± 0.96%, P < 0.001) and H929 cells (7.29± 0.14%, P
< 0.001; Figure 1D).
DHA Treatment Increases the
Concentration of ROS in MM Cell Lines
ROS serve an important role during apoptosis (31) and ROS
concentration is the most intuitive indicator to evaluate the
oxidant activity of ART and DHA (32). Thus, the ROS levels in
MM cells treated with ART or DHA were determined. As shown
in Figure 2A, DHA significantly increased ROS production
compared with ART treatment (P < 0.001) in ARP1 and H929
cells. At 2.5µM DHA in ARP1 cells, the generation of ROS
(1.65 ± 0.06) was significantly higher than that in the untreated
cells (1.00 ± 0.02) and ART-treated cells (1.15 ± 0.10). Similar
results were observed in H929 cells and at other concentrations,
suggesting that DHA increased intracellular ROS production
compared with the ART and untreated cells (Figure 2A).
Previous studies have reported that ART treatments, in the
presence of free iron, result in the production of alkylating
agents which damage cancer cells (33). Therefore, the effect
of DHA on intracellular iron in MM cells was examined.
The fluorescence intensity of intracellular iron staining was
determined using Calcein-AM after 0, 24, 48 and 72 h of
treatment and flow cytometry (Figure 2B). The cytoplasmic Fe2+
of MM cells was labeled using Calcein-AM and an increase in
fluorescence intensity represented reduced ferrous iron content.
The fluorescence intensity of calcein was lower in ARP1 (0 vs.
48 h, 715.61 ± 21.72 vs. 209.46 ± 54.75) and in H929 cells (0
vs. 48 h, 547.73 ± 36.4 vs 149.07 ± 41.34) treated with DHA
for 48 h. Calcein fluorescence intensity was significantly lower
in cells treated with DHA after 48 h than in ART-treated and
untreated cells.
To determine whether ART and DHA altered mitochondrial
OCR, MM cells were treated with ART or DHA for 48 h.
Oligomycin A was added to the cells to examine oxygen
consumption coupled with ATP synthesis. The uncoupler
carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone
(FCCP) was added to determine the maximal respiratory
capacity. Antimycin A and rotenone were used to determine
the spare respiratory capacity. As shown in Figure 2C, only
treatment with DHA resulted in a significant increase in OCR,
suggesting that DHA, but not ART, increases the concentration
of ROS primarily through increasing mitochondrial OCR.
DHA Induces the Mitochondrial Apoptosis
Pathway in MM
To confirm the effect of DHA on MM cell apoptosis and the
involvement of the mitochondrial pathway, the expression of
caspase-3, PARP, Bcl-2, and Bad were determined, which were
indicators of apoptosis in a number of different types of cancer
(34). Western blot showed that cleaved caspase-3 and PARP
expression levels in ARP1 and H929 cells treated with DHA
were significantly increased compared with cells treated with
ART or untreated cells after 12, 24, and 48 h (Figure 3A). Bcl-2
expression levels were significantly decreased in cells treated with
DHA after 24 h (Figure 3B). To further confirm the involvement
of mitochondria-dependent apoptosis in cells treated with DHA,
Bad expression was measured. As shown in Figure 3C, DHA
treatment downregulated the expression of Bad in both ARP1
and H929 cells in a time-dependent manner.
DHA Overcomes Resistance to Dexa in MM
Since Bcl-2 is a typical marker for Dexa resistance MM patients,
we further assessed the efficacy of DHA for treatment of
Dexa-resistant MM (35). Paired Dexa-sensitive (MM.1S) and
Dexa-resistant (MM.1R) MM cell lines were utilized, which
were established from peripheral blood of the same MM
patient and sensitive/resistant to Dexa, respectively (36). The
viability of MM.1S and MM.1R cells significantly reduced in
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FIGURE 2 | DHA increases the concentration of reactive oxygen species (ROS) in MM cell lines. (A) ROS determination assay. ARP1 and H929 cells were treated with
different concentrations of ART or DHA for 48 h, and the percentage of DCFHDA positive cells was detected by flow cytometry. (B) The measurement of Fe2+ levels.
Mean fluorescence intensity of ARP1 and H929 cells treated with ART or DHA for different time points (24, 48, and 72 h) was measured by flow cytometry. (C) The
measurement of OCR. The oxygen consumption rate was determined by O2k (see Materials and Methods). Data statistics were analyzed by Student’s t-test. *P <
0.05, **P < 0.01, ***P < 0.001.
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FIGURE 3 | DHA induces caspase-mediated apoptosis in MM cell lines. (A–C) The protein levels of caspase-3, PARP, Bcl-2, and Bad were determined by western
blotting in MM cells. The results showed that caspase-3 and PARP were increased after 12 h, while Bcl-2 and Bad were decreased after 12 h.
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FIGURE 4 | DHA overcomes dexamethasone resistance in multiple myeloma. (A) The MTT assay. DHA suppresses the proliferation of ARP1 and H929 cells. (B) DHA
synergistically enhances the effect of Dexa. (C) The MTT assay. The combination of DHA and Dexa significantly inhibits the growth of CD138 positive cells. (D) The
apoptosis of MM.1S and MM.1R cells was measured by staining with Annexin V and PI, which was followed by flow cytometry analysis. *P < 0.05, ***P < 0.001.
Frontiers in Oncology | www.frontiersin.org 8 May 2020 | Volume 10 | Article 767
Chen et al. Dihydroartemisinin for Multiple Myeloma
FIGURE 5 | DHA in combination with Dexa induced more translocation of Cyt C from the mitochondria to the cytoplasm. (A,B) Determination of ROS and
mitochondrial membrane potential. Fluorescence intensity is detected by flow cytometry. (C–G) The western blotting results showed that Cyt C and cleaved
caspase-3 are increased after treatment with DHA plus Dexa and Bcl-2 expression is associated with Dexa administration in a time- and concentration-dependent
manner. **P < 0.01, ***P < 0.001.
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a concentration-dependent manner (Figure 4A). Of note, the
MM.1R cells exhibited some sensitivity to DHA.
As Dexa is the most widely used treatment for patients with
MM despite the development of drug resistance (37), the effect
of DHA in combination with Dexa was determined. As shown
in Figure 4B, a combination of DHA and Dexa significantly
reduced the viability of MM.1S (combination index, CI, of
17.5µM DHA with 60µM Dexa, 0.269) and MM.1R cells (CI of
17.5µM DHA with 15µM Dexa, 0.167). Comparable results of
combined treatment and Dexa were observed, confirming that
combined treatment significantly reduced viability compared
with either treatment alone, irrespective of the Dexa dose.
To determine the clinical potential of DHA combined with
Dexa, MM cells obtained from the MM patients were treated
with the drugs to evaluate their effects on growth in short-
term cultures for 12 h. The CD138+ cells showed significantly
reduced growth when treated with the combination of drugs
compared with 7.5µM Dexa or 120µM DHA alone (both P
< 0.05; Figure 4C). Additionally, apoptosis was detected using
flow cytometry, and it was demonstrated that both MM.1S and
MM.1R cells treated with the combination of drugs exhibited
increased apoptosis compared with Dexa or DHA alone (both
P < 0.001; Figure 4D), consistent with the results of ARP1 and
H929 cells treated with the drugs either alone or in combination.
DHA Combined With Dexa Increases
Translocation of Cytochrome C (cyt C)
From the Mitochondria to the Cytoplasm
In order to detect the mechanism through which DHA
overcomes Dexa resistance, we further explored if DHA
combined with Dexa could increase oxidative stress and ROS
production in MM.1S and MM.1R cells. As shown in Figure 5A,
the levels of ROS in cells treated with a combination of
drugs were significantly higher than those in cells treated with
either treatment alone. Treatment with Dexa or DHA alone,
or combined resulted in a loss in 1ψm, which is represented
by an increase in JC-1 green fluorescence (Figure 5B). The
combination treatment (2965.06± 64.52 inMM.1S cells; 2918.14
± 26.21 in MM.1R cells) was significantly more effective
compared with Dexa alone (2579.85± 36.75 in MM.1S cells, P <
0.01; 2492.58 ± 36.39 in MM.1R cells, P < 0.01) and DHA alone
(2632.60 ± 8.91 in MM.1S cells, P < 0.001; 2477.90 ± 84.07 in
MM.1R cells, P < 0.01).
The alterations of 1ψm, induced by a combination of drugs,
are associated with translocation of mitochondrial proteins to
the cytosol, including Cyt C (38). As shown in Figure 5C,
treatment with the combination of drugs resulted in increased
translocation of Cyt C to the cytosol compared with treatment
with either Dexa or DHA alone. It has been reported that
during mitochondrial permeability transition, Cyt C activates
caspase-3 (39). The expression levels of cleaved caspase-3 were
increased by DHA and Dexa alone, and further increased
when cells were treated with a combination of the two drugs
(Figure 5D). Cyt Ctranslocation from the mitochondria to the
cytosol depends partly on the expression of Bcl-2 (40), thus Bcl-2
expression in cells treated with Dexa, DHA, or both combined
was examined. Additionally, Dexa increased Bcl-2 expression
in a time-dependent manner (0–96 h) peaking at 48 and 72 h
with the concentration of 3.75µM, in MM.1S and MM.1R cells
(Figure 5E), suggesting that Dexa may increase Bcl-2 expression
during the first 24 h. However, increasing the concentration of
Dexa (0, 3.75, 7.5, 15, 30, 60, and 120µM) within 24 h resulted
in a decrease in Bcl-2 expression including in the MM.1R cells
(Figure 5F). Irrespective of the concentration of Dexa used,
the combination treatment restored the Dexa-induced Bcl-2
expression in the resistant cells, suggesting that DHA treatment
was able to overcome Dexa resistance.
These results show that the cytotoxic effects of DHA combined
with Dexa were mediated by increased ROS production, altering
1ψm, reversing changes to Bcl-2 expression mediated by Dexa,
increasing release of mitochondrial Cyt C, activating caspase-3,
and finally inducing caspase-mediated apoptosis.
Anti-MM Activity of DHA Combined With
Dexa in a MM Xenograft Mouse Model
To replicate our findings in vivo, an MM xenograft mouse
model was used to evaluate the antitumor activity of DHA
in combination with Dexa. NOD-SCID mice were injected
with MM.1S or MM.1R cells subcutaneously; tumor neoplasms
in untreated mice developed over ∼1 month, whereas tumor
growth of the Dexa- or DHA-treated mice developed slower
comparedwith the untreatedmice (Figure 6A). The combination
treatment resulted in significantly reduced tumor growth
compared with either treatment alone in mice injected with
MM.1R cells (COM 1,217.76 ± 343.15 mm3 vs. Dexa 2079.50
± 507.87 mm3, P < 0.001; COM vs. DHA 1875.53 ± 475.61
mm3, P < 0.05). However, this was not observed in mice injected
with MM.1S cells (Figure 6A). After 39 days, the weight of
tumors from the mice treated with both drugs (0.24 ± 0.17 g
in MM.1S; 0.65 ± 0.12 g in MM.1R cells) was significantly
reduced compared with that noted for untreated mice (2.02 ±
0.27 g in MM.1S; 2.65 ± 0.72 g in MM.1R), Dexa treated mice
(0.98 ± 0.22 g in MM.1S; 1.62 ± 0.34 g in MM.1R), and DHA-
treated mice (0.99 ± 0.19 g in MM.1S; 1.28 ± 0.20 g in MM.1R)
(Figures 6B,C).
DISCUSSION
Despite the advancements in therapeutic target discovery
and targeted therapy, MM is still incurable. Typically, MM
patients respond to the treatment initially, but the majority
of them ultimately relapse. Therefore, the development of
novel treatment is extremely urgent. Artemisinin-type drugs are
typically metabolized in vivo to the active metabolite DHA (41),
and the anticancer effects of ART and its derivative DHA have
been demonstrated in a number of different types of cancer (41–
45). For instance, in breast cancer, DHA induced apoptosis and
G0/G1 arrest by activating Bid, increased the expression of Bim,
decreased the expression of Bcl-2, induced the translocation of
Cyt C from the mitochondria to the cytosol, and increased the
expression of caspase-8, and cleaved caspase-9 (43, 44). However,
so far, there have been no studies examining the effects of DHA
Frontiers in Oncology | www.frontiersin.org 10 May 2020 | Volume 10 | Article 767
Chen et al. Dihydroartemisinin for Multiple Myeloma
FIGURE 6 | Anti-MM activity of DHA in combination with Dexa in MM xenograft mouse models. (A) The effect of DHA combined with Dexa (COM) was examined in
subcutaneous transplantation mouse models using MM.1S and MM.1R cell lines. The result indicated that COM significantly inhibited MM.1R tumor growth compared
with the DHA and ART group. (B) After treatment, the tumor weight of COM group was lower than that of the DHA or ART group. *P < 0.05, **P < 0.01. (C) The
NOD-SCID mice injected subcutaneously with MM.1S (left) and MM.1R (right) cells were sacrificed and tumors were isolated on Day 39.
on MM, and in particular, the combination of DHA with other
chemotherapeutic drugs including Dexa on MM. Our study first
evaluated the effects of ART and DHA on MM in vitro and
in vivo, and demonstrated that DHA could possess a greater
efficacy than ART against MM (Figures 1A,B). At the cellular
level, ART could only induce weak apoptosis of MM cells and
decrease the G2/M staged cells (Figures 1C,D) compared to
DHA, suggesting that ART could be converted into activated
DHA in the microenvironment of MM cells. The in vivo study
in 5TMM3VT myeloma C57BL/KaLwRij mice showed that both
ART and DHA could improve the survival rate of the mice;
however, MMmice treated with DHA had a longer survival than
ART-treated mice. This phenomenon may be due to the fact that
ART in vivo is not completely converted to the activated DHA.
Consistent with previous reports that DHA prevented MM
tumor growth through a caspase-mediated pathway (43), the
current study found that the mitochondria were the primary
target by which DHA exerted its effects. DHA activated
apoptosis via caspase-3, followed by PARP cleavage (Figure 3A),
and decreased 1ψm (Figure 5B), which in turn, increased
the translocation of Cyt C from the mitochondria to the
cytoplasm (Figure 5C) (45). Additionally, DHA interacted with
iron and activated oxygen consumption (Figures 2B,C), resulting
in increased production of ROS (Figures 2A, 5A), and this
was assumed to be the after-effects of permeabilization of the
outer mitochondrial membrane (46), since outer mitochondrial
membrane permeabilization resulted in a loss of 1ψm and
an increase in ROS levels (47). For MM treatment, the drug
resistance and its related relapse are the major clinical obstacles,
we further explored that DHA is effective in treating drug-
resistant MM (Figures 4A,B). DHA-induced mitochondrial
apoptotic pathways are largely related to those pathways affected
by Dexa. Dexa increases the releasing of the mitochondrial
apoptogenic factors Second mitochondrial-derived activator
(Smac)/DIABLO and Cyt C from the mitochondria to the
cytosol, and activates the SAPK/JNK-independent pathway,
which is associated with downregulation of MAPK and p70S6K
(48). However, DHA reduced the expression of Bad and Bcl-
2 (Figures 3B,C), while Dexa increased Bcl-2 expression in
both MM.1S and MM.1R cells within the first 48 h at lower
concentrations (Figure 5E) and suppressed the growth of MM
cells at higher concentrations (Figure 5F). Therefore, we infer
that DHA might counteract the effects of Dexa to balance
Bcl-2 expression (Figure 5G), thus regulating the translocation
of Cyt C to further promote cell apoptosis (summarized
in Figure 7). This hypothesis is further strengthened by the
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FIGURE 7 | Summary of the effect of DHA and Dexa on MM. In previous studies, DHA was found to influence the progression of different cancers by regulating the
expression of mitochondrial, nucleus and cytoplasmic proteins. On protein level, Dexa inhibits the proliferation of MM cells by mainly adjusting the expression of Smac,
cytochrome C, caspase-3, caspase-9, MAPK and p70S6K. In our study, DHA was found to not only induce the mitochondrial apoptosis pathway, but also inhibit
Bcl-2 expression induced by Dexa. A synergism of DHA and Dexa increases ROS levels and translocation of cytochrome C from mitochondria to the cytoplasm, and
then alters mitochondrial membrane potential as well as caspase-mediated apoptosis. (The triangle on the left shows the effect of Dexa on the protein expression, and
the other side shows the effect of DHA on the protein expression. The red triangle indicates an increase in protein expression and the blue triangle indicates a
decrease in the protein expression. The blue characters and lines represent Dexa-acting proteins. The black line and the bold characters represent the summary of
this study, and the gray line represents the summary of the literature study).
report that Bcl-2 inhibits the translocation of Cyt C from
the mitochondria to the cytoplasm (49), and Cyt C increases
caspase-3 expression and ultimately induces caspase-3-mediated
apoptosis (50).
Therefore, we further confirmed that DHA could overcome
the Dexa resistance in MM (Figures 4A–C). DHA-induced
cytotoxicity in MM.1S and MM.1R cells is enhanced by Dexa,
suggesting that the apoptotic signaling cascades by which DHA
and Dexa exert their effects may be different (Figure 4D). It has
been demonstrated that Dexa-induced caspase-9 activation via a
Smac-dependent and Cyt C-independent pathway (51), whereas,
in the present study, DHA activated caspase-3 and increased the
release of Cyt C from the mitochondria (Figures 5C,D). DHA
synergistically augmented the effect of Dexa-induced cytotoxicity
(Figure 4B), including the decrease in proliferation and the
increase in apoptosis of MM cells (Figure 4D). Importantly,
DHA re-sensitized MM.1R cells to Dexa in vitro and in vivo
(Figures 6A–C). Through these mechanisms, DHA alone not
only exhibits anticancer effects in MM but also augments and
complements the effects of the widely used anti-MM agent Dexa.
These data provide a rationale for future clinical studies to
develop a novel therapeutic regimen comprising DHA alone or in
combination with other agents for patients with MM particularly
for relapsed/refractory MM patients.
In conclusion, our study provides the first evidence that
DHA may be an effective standalone treatment for MM patients
and that it can overcome Dexa resistance. Mechanistically,
DHA prevents MM development and progression through
mitochondrial apoptotic pathway involving Fe2+ and oxygen.
DHA augments the effects of Dexa, resulting in increased
production of ROS and translocation of Cyt C from the
mitochondria to the cytoplasm, and downregulates Dexa-
induced expression of Bcl-2, a biomarker of Dexa resistance.
Therefore, DHA may be a promising therapeutic option
for patients with refractory/relapsed MM. Further studies
are necessary to determine the clinical efficacy and detailed
therapeutic targets.
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